Kelun-Biotech, sacituzumab tirumotecan, sac-TMT, SKB264, MK-2870, OptiTROP-Lung06, non-small cell lung cancer, NSCLC, pembrolizumab, TROP2, antibody-drug conjugate, ADC, Phase 3 clinical trial

Chengdu, China, October 25, 2026 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced positive results from the Phase 3 OptiTROP-Lung06 clinical...